INR is calculated by dividing a patient’s prothrombin time (PT) by a control PT value, then raising that ratio to the power of a correction factor called the International Sensitivity Index (ISI). The full formula is: INR = (Patient PT ÷ Control PT)ISI. Each piece of this equation serves a specific purpose, and understanding them explains why INR exists in the first place.
What Each Part of the Formula Means
The foundation of INR is the prothrombin time test. PT measures how many seconds it takes a sample of your blood plasma to form a clot after a lab technician adds a substance called thromboplastin, which is a mixture of tissue factor, calcium, and phospholipid that triggers the clotting cascade. Blood is drawn into a tube containing sodium citrate, which temporarily prevents clotting by binding calcium. When calcium chloride is added back in the lab, clotting resumes and the clock starts. A normal PT typically falls around 11 to 13.5 seconds.
The control PT in the formula is the average clotting time for normal, healthy plasma tested with the same reagent. Dividing your PT by this control gives a simple ratio. If your blood takes twice as long to clot as normal plasma, that ratio is 2.0.
The problem is that different thromboplastin reagents vary in sensitivity. A reagent made by one manufacturer might produce a PT of 24 seconds for the same patient whose blood clots in 30 seconds with a different brand’s reagent. Without correction, two labs testing the same blood sample could report meaningfully different results. This is where the ISI comes in.
How the ISI Corrects for Lab Differences
The International Sensitivity Index is a number assigned to each thromboplastin reagent by its manufacturer, calibrated against a reference standard maintained by the World Health Organization. The WHO’s Expert Committee on Biological Standardization maintains international reference preparations of thromboplastin and publishes guidelines for how manufacturers should calibrate against them. An ISI of 1.0 means the reagent behaves identically to the WHO reference. Most commercial reagents have ISI values between 1.0 and 2.0.
Raising the PT ratio to the power of the ISI mathematically adjusts for reagent sensitivity. A reagent with a higher ISI is less sensitive to clotting factor deficiencies, meaning it produces smaller changes in PT for the same degree of anticoagulation. The exponential correction compensates for this, so a patient’s INR should come out the same regardless of which lab runs the test. Lower ISI values produce more precise INR results because less mathematical amplification is needed. Research published in the British Journal of Haematology found that interlaboratory variability of INR increases roughly in proportion to the ISI value, which is why manufacturers are encouraged to produce reagents with ISI values as close to 1.0 as possible.
A Quick Example
Say your PT comes back at 27 seconds. The lab’s control PT for normal plasma is 13 seconds, and the thromboplastin reagent has an ISI of 1.2. First, divide: 27 ÷ 13 = 2.08. Then raise that ratio to the 1.2 power: 2.081.2 = approximately 2.3. Your INR is 2.3. If a different lab uses a reagent with an ISI of 1.0, the raw PT numbers would differ, but the final INR should land close to that same 2.3.
Why INR Exists Instead of Just Using PT
Before INR was standardized, doctors had to interpret PT results knowing which reagent a particular lab used, and transferring care between hospitals was a guessing game. The WHO introduced the INR system specifically to create a universal number for monitoring blood-thinning medications like warfarin. A patient with an INR of 2.5 in Tokyo should have the same degree of anticoagulation as a patient reading 2.5 in Chicago.
Target Ranges for Common Conditions
A person not taking blood thinners has an INR close to 1.0. For most people on warfarin therapy, the therapeutic target falls between 2.0 and 3.0. This range applies to common indications like atrial fibrillation and deep vein thrombosis.
Mechanical heart valves require tighter or higher targets depending on the valve type and location. Patients with a standard bileaflet mechanical aortic valve and no additional clot risk factors typically aim for an INR of 2.5. That target rises to 3.0 for patients with a mechanical mitral or tricuspid valve, older ball-in-cage aortic valves, or anyone with additional risk factors such as a history of blood clots, atrial fibrillation, or reduced heart function. One newer aortic valve design allows a lower target of 1.5 to 2.0 after the first three months.
How Home Monitors Compare to Lab Tests
Portable fingerstick INR devices work on a different principle than lab analyzers. Instead of measuring how long plasma takes to clot in a tube, they apply a drop of capillary blood from a finger prick onto a test strip containing pre-printed reagents. Electrodes in the strip detect changes in electrical current as the blood coagulates, and the device calculates an INR from those changes.
Lab analyzers, by contrast, use venous blood drawn into citrate tubes. Fully automated platforms add thromboplastin to the separated plasma and detect clot formation through changes in viscosity, often by tracking the oscillation of a tiny steel ball suspended in an electromagnetic field.
Despite these very different approaches, the two methods agree well. In a study of 211 paired measurements, 90% of fingerstick results fell within 30% of the lab value, which is the international standard for acceptable agreement. The overall correlation between methods was 0.91 out of 1.0. Accuracy drops at higher INR values, though. When the lab INR exceeded 4.0, variability between the two methods increased significantly. If your INR tends to run high, lab-drawn results are more reliable.
INR Beyond Blood Thinners
INR also plays a central role in assessing liver disease severity. The MELD score, used to prioritize patients for liver transplantation, is calculated from three lab values: INR, creatinine, and bilirubin. Of the three, INR carries the most mathematical weight in the formula.
There is an important caveat here. The INR system was designed and validated for patients on warfarin, who have a predictable pattern of reduced clotting factors. Liver disease creates a far more complex picture. Warfarin lowers only vitamin K-dependent clotting factors, while a failing liver may also underproduce other clotting factors, fibrinogen, and even natural anticoagulant proteins like protein C and protein S. Because of this more complicated coagulation profile, the ISI values calibrated for warfarin monitoring may not translate perfectly to liver disease. Two patients with the same INR, one on warfarin and one with cirrhosis, can have very different actual bleeding and clotting risks.